Login to Your Account



Innovent, Hanmi ink global I-O bispecific deal

By Shannon Ellis
Staff Writer

Friday, March 31, 2017

SHANGHAI – Suzhou-based Innovent Biologics Inc. and Hanmi Pharmaceuticals Co. Ltd., of Seoul, will pair up to co-develop and co-commercialize a bispecific immuno-oncology antibody.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription